Clinicians should use a structured interview in people with Alzheimer’s disease to identify pain that might be otherwise overlooked.

Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.

Two brain signaling pathways have overlapping functions in regulating anxiety, suggesting that therapeutics aimed at one or the other will impact both.

A new protein structure may guide the development of Alzheimer's therapeutics.

Some memory deficits observed in Alzheimer’s disease may be due to co-morbid illnesses – not the disease itself – and may be reversed by lifestyle changes or pharmacologic interventions.

Vanderbilt researchers will discuss their groundbreaking studies on Alzheimer’s disease and dementia at an upcoming forum, and the public is invited to attend.

Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.